X
skip to main content
Logo
  • May 29, 2017

    TFRI's Dr. Victor Ling recognized for breakthrough in fighting drug-resistant cancers

    Dr. Victor Ling, president and scientific director of The Terry Fox Research Institute, has been recognized by The Vancouver Sun for his breakthrough in fighting drug-resistant cancers.

  • May 24, 2017

    MATE2 expression a negative predictive biomarker to metformin’s efficacy in cancer treatment, study suggests

    The drug metformin is typically used to treat Type 2 diabetes, and some cancer patients have shown improved outcome when given the drug. A recent study by TFRI’s hypoxia group sheds new light on biomarkers that may indicate the drug’s efficacy in patients.

  • May 24, 2017

    Groundbreaking study sheds light on signaling molecules that control human hematopoietic stem cell survival and growth

    TFRI’s long-funded program project on human leukemia has made groundbreaking progress in the quest to expand human blood stem cells for therapeutic purposes.

  • May 24, 2017

    Novel 17-gene test predicts if patients with aggressive leukemia will respond to treatment or not

    What if there was a way to predict if leukemia patients would respond to standard treatment or not? A TFRI-funded team has developed a novel, 17-gene signature test from leukemia stem cells (LSCs) that determines just that.

  • May 24, 2017

    Canadian study identifies predictive genomic signature for high-risk prostate cancer

    Understanding why some prostate cancer tumours are indolent while others eventually kill patients is the focus of many within the global cancer research community. A top Canadian research team has provided new answers with the potential to change the way aggressive tumours are treated and, importantly, improve cure rates.

  • May 24, 2017

    Complement inhibitors decrease neutralization of some oncolytic viruses, increase treatment efficacy

    The use of oncolytic viruses to stimulate a patient’s immune system as well as directly kill tumour cells is a novel approach to eradicating cancer, but antibodies that permanently inactivate the virus are often generated that counter treatment efficacy. An Ottawa-based lab has come up with a way of countering this problem by using a complement inhibitor that prevents the virus’ neutralization, thereby ensuring viral vectors reach their target.

  • May 18, 2017

    B.C. team study detects rare ovarian cancer mutation in ctDNA of patients

    The finding by a B.C. team studying rare and forme fruste tumours is important in that it may help to identify women at risk of relapse for the disease, as well as to provide a non-invasive way to monitor patients in follow-up.

  • May 17, 2017

    Terry Fox Foundation is media outlet’s top pick for donating to cancer research

    An article published in The National Post in mid-May has identified the Terry Fox Foundation as one of the best places to donate to cancer research in Canada.

Back to Top